Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In West To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 23, 2025 (GLOBE N ...

LOS ANGELES, May 22, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN WEST PHARMACEUTICAL SERVICES, INC. (WST), CLICK HERE BEFORE JULY 7, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.What Is The Lawsuit About? The complaint file ...

诉讼案件概述 - 律师事务所Levi & Korsinsky针对West Pharmaceutical Services Inc（NYSE: WST）发起证券集体诉讼，旨在为2023年2月16日至2025年2月12日期间因涉嫌证券欺诈遭受损失的投资者追偿损失 [1][2] 诉讼指控内容 - 公司被指控在以下方面存在虚假陈述或隐瞒： - 尽管声称对客户需求有清晰可见性并将阻力归因于临时性COVID相关产品去库存，但实际其高利润率HVP产品组合正经历持续且严重的去库存 [3] - 标榜为高利润率增长产品的SmartDose设备，由于运营效率低下严重稀释了公司整体利润率 [3] - 上述利润率压力导致公司面临退出长期客户连续血糖监测合同等成本高昂的重组活动风险 [3] - 公司管理层关于业务、运营及前景的积极陈述因此缺乏合理依据或存在重大误导性 [3] 诉讼程序安排 - 受影响投资者需在2025年7月7日前向法院申请作为首席原告，但参与赔偿无需承担任何自付费用 [4] 律师事务所背景 - Levi & Korsinsky过去20年累计为股东追回数亿美元赔偿，拥有70多名员工的团队专精复杂证券诉讼，连续七年入选ISS证券集体诉讼服务全美前50强律所 [5]

NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=149537&from=4CLAS ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=149365&fro ...

BENSALEM, Pa., May 20, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN WEST PHARMACEUTICAL SERVICES, INC. (WST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JULY 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Cont ...

集体诉讼案件 - 罗森律师事务所代表在2023年2月16日至2025年2月12日期间购买West Pharmaceutical Services公司普通股的投资者提起集体诉讼 [1] - 诉讼指控被告在集体诉讼期间作出虚假和误导性陈述或未能披露重要信息 [5] - 投资者可在2025年7月7日前申请成为首席原告 [1][3] 诉讼指控内容 - West公司声称对客户需求有清晰了解并将阻力归因于临时性COVID相关产品去库存 但实际上其高利润率的高价值产品组合正经历持续去库存 [5] - 公司SmartDose设备虽然定位为高利润率增长产品 但由于运营效率低下严重稀释了利润空间 [5] - 利润率压力导致公司可能退出与长期客户的连续血糖监测合同 并面临高成本重组活动 [5] 律所背景 - 罗森律师事务所在证券集体诉讼领域具有丰富经验 2017年ISS证券集体诉讼服务排名第一 [4] - 该律所曾创下针对中国公司的最大证券集体诉讼和解金额 2019年单年为投资者追回4.38亿美元 [4] - 创始合伙人Laurence Rosen被Law360评为原告律师界泰斗 多名律师获得Lawdragon和Super Lawyers认可 [4] 参与方式 - 投资者可通过网站提交表格或联系Phillip Kim律师参与集体诉讼 [3][6] - 投资者可选择自行聘请律师或保持缺席成员身份 未来获得赔偿的能力不取决于是否担任首席原告 [7] - 律所在LinkedIn Twitter和Facebook上提供案件更新 [8]

公司诉讼案件 - 西氏医药服务公司因涉嫌违反1934年证券交易法被提起集体诉讼 案件编号为No 25-cv-02285 [1] - 诉讼指控公司在2023年2月16日至2025年2月12日期间做出虚假和/或误导性陈述 [1][3] - 诉讼涉及公司高管及前高管 原告为新英格兰卡车司机养老金基金 [1] 公司业务情况 - 西氏医药主要从事注射药物和医疗产品的密封包装和给药系统设计与制造 [2] - 公司高利润的高价值产品组合持续经历显著去库存 与公司声称的"临时性COVID相关去库存"不符 [3] - SmartDose设备因运营效率低下严重稀释公司利润率 该产品本被定位为高利润增长产品 [3] 财务与运营问题 - 公司2025年收入指引为28 8-29 1亿美元 大幅低于预期 [4] - 利润率压力导致公司退出长期客户的连续血糖监测(CGM)合同 [3] - SmartDose可穿戴注射器因降价将在2025年继续稀释利润率 [4] 市场反应 - 2025年2月13日公司发布上述消息后 股价暴跌超过38% [4] - 公司解释业绩不佳部分原因是合同制造业务面临挑战 包括失去两个主要CGM客户 [4]

NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a memb ...

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=148835&from=4CLAS ...